TScan Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
Provided By GlobeNewswire
Last update: May 6, 2025
Updates from the PLEXI-T™ solid tumor and ALLOHA™ heme Phase 1 clinical trials anticipated by end of year
On-track to file IND application for TSC-102-A0301 (CD45; HLA-A*03:01) to FDA in the second half of the year
Read more at globenewswire.comNASDAQ:TCRX (9/26/2025, 10:27:01 AM)
1.77
-0.01 (-0.56%)
Find more stocks in the Stock Screener
